The US patent for our DigitHal® technology for inhaled treatments was issued this week.
This is a big step for this project, which specifically addresses non-observance by asthmatic patients, hence allowing better support from caregivers. DigitHal® provides real-time information on the inhalation of the drug and aims to improve the method of patient administration. This new device will in fact offer a more relevant solution for taking and monitoring any inhaled treatment.
DigitHal® : two Galien Medstartup rewards
DigitHal® is consequently moving forward on its America journey as this particular project had already been twice rewarded in October 2017 during the prestigious Galien Medstartup award ceremony in New York City. Indeed, our team went back to France after winning the prizes in the categories Best collaboration with an academic partner (in partnership with the Virginia Commonwealth University) and Best use of technologies involving patients and their health.
The US patent is therefore an important step for this technology made in Normandy.